Tolrestat

Drug Profile

Tolrestat

Alternative Names: Alredase; AY 27773; Lorestat

Latest Information Update: 19 Dec 1996

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Wyeth
  • Developer Recordati; Wyeth
  • Class Antihyperglycaemics
  • Mechanism of Action Aldehyde reductase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Market Withdrawal Diabetic complications

Most Recent Events

  • 19 Dec 1996 A meta-analysis has been added to the therapeutic trials section
  • 23 Oct 1996 Discontinued-III for Diabetic complications in France (PO)
  • 23 Oct 1996 Discontinued-preregistration for Diabetic complications in Australia (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top